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Abstract 
 
Purpose: Approximately 40% of all glioblastomas have amplified the epidermal growth factor 
receptor (EGFR) gene and about half of these tumors express the EGFRvIII variant 
characterized by an in-frame deletion of exons 2-7. The prognostic role of EGFRvIII in 
EGFR-amplified glioblastoma patients and changes in EGFRvIII expression in recurrent 
versus primary glioblastomas remain controversial, but such data are highly relevant for the 
clinical evaluation of EGFRvIII-targeted therapeutic agents. 
Experimental design: EGFR-amplified glioblastomas from 106 patients treated according to 
standard of care were assessed for EGFRvIII positivity. Changes in EGFR amplification and 
EGFRvIII status from primary to recurrent glioblastomas were evaluated in 40 patients with 
EGFR-amplified tumors, including 25 EGFRvIII-positive cases, and 33 patients with EGFR-
non-amplified tumors. EGFR single nucleotide variants (SNVs) were additionally assessed in 
27 patients. Data were correlated with outcome including validation in an independent cohort 
of 150 glioblastoma patients from The Cancer Genome Atlas (TCGA) consortium. 
Results: Sixty of 106 EGFR-amplified glioblastoma patients had EGFRvIII-mutant tumors 
(56.6%). EGFRvIII positivity was not associated with different progression-free survival 
(HR=0.91, 95%CI 0.61-1.36, p=0.644) or overall survival (HR=1.05, 95%CI 0.70-1.58, 
p=0.798). EGFRvIII status was unchanged at recurrence in 35 of 40 patients with EGFR-
amplified primary tumors (87.5%). In four patients, EGFRvIII positivity was lost at recurrence 
while one recurrent glioblastoma gained EGFRvIII positivity. None of 33 EGFR-non-amplified 
glioblastomas acquired EGFR amplification or EGFRvIII at recurrence. EGFR SNVs were 
frequent in EGFR-amplified tumors, but were not linked to survival. 
Conclusions: EGFRvIII and EGFR SNVs are not prognostic in EGFR-amplified glioblastoma 
patients. EGFR amplification is retained in recurrent glioblastomas. Most EGFRvIII-positive 
glioblastomas maintain EGFRvIII positivity at recurrence. However, EGFRvIII expression 
may change in a subset of patients at recurrence, thus repeated biopsy with reassessment of 
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EGFRvIII status is recommended for recurrent glioblastoma patients to receive EGFRvIII-
targeting agents. 
 
Abstract word count: 294 words 
 
Statement of translational relevance 
The epidermal growth factor receptor (EGFR) gene is amplified in approximately 40% of 
glioblastomas. About half of the EGFR-amplified tumors are positive for the tumor-specific 
EGFRvIII deletion variant and EGFR single nucleotide variants (SNVs) are also commonly 
associated with EGFR amplification. Various novel therapeutic agents targeting 
overexpressed EGFR or EGFRvIII proteins are currently being developed. The present study 
indicates that positivity for EGFRvIII and presence of one or more EGFR SNVs are not 
prognostic in patients with EGFR-amplified glioblastomas. In addition, we show that EGFR 
amplification is generally maintained between primary and recurrent glioblastomas. However, 
the EGFRvIII status in EGFR-amplified glioblastomas may change upon tumor recurrence in 
a subset of patients, suggesting a role for reassessment of the EGFRvIII status in recurrent 
glioblastoma patients to receive an EGFRvIII-targeting treatment. 
 
Abbreviations 
CI, confidence interval; CNS, central nervous system; EGFR, epidermal growth factor 
receptor; EGFRvIII, EGFR variant III; GGN, German Glioma Network; HR, hazard ratio; IDH, 
isocitrate dehydrogenase; IHC, immunohistochemistry; KPS, Karnofsky Performance Score; 
MGMT, O6-methylguanine-DNA methyltransferase; MSP, methylation-speficic PCR; NGS, 
next generation sequencing; OS, overall survival; PD, progressive disease; PFS, 
progression-free survival; PT, primary tumor; RT, recurrent tumor; RTK, receptor tyrosine 
kinase; RT-PCR, reverse transcriptase-PCR; SNV, single nucleotide variant; TCGA, The 
Cancer Genome Atlas; TMZ, temozolomide; TMZ/radiotherapy→TMZ, radiotherapy with 
concomitant and maintenance TMZ.
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Introduction 
 
The epidermal growth factor receptor (EGFR) gene is the most commonly amplified and 
overexpressed proto-oncogene and a frequent mutational target in glioblastoma (for reviews 
see 1, 2). EGFR gene amplification is detectable in approximately 40% of all glioblastomas 
(3-5) and is particularly common in the classic or receptor tyrosine kinase (RTK) type 2 
molecular subtype of isocitrate dehydrogenase (IDH)-wildtype glioblastoma (6).  
Approximately 50% of EGFR-amplified glioblastomas do not only amplify and overexpress 
the wildtype EGFR gene but additionally carry a tumor-specific deletion variant (EGFRvIII) 
that is characterized by an in-frame deletion of exons 2-7 (7, 8). This particular 
rearrangement results in overexpression of a truncated receptor protein that lacks major 
parts of the extracellular domain, is unable to bind its ligands and is constitutively active, thus 
constituting a prototypic oncoprotein (for review see 9). Futhermore, the EGFRvIII protein 
carries a unique peptide sequence generated by the fusion of exons 1 and 8 which may 
serve as a tumor-specific target for anti-EGFRvIII immunotherapy approaches including 
antibody-based approaches, genetically modified T cells, as well as peptide-based 
vaccination strategies (for review see 10). 
 Standardization of detection and quantification of EGFR amplification and EGFRvIII 
mutation in routinely processed tumor tissues remain challenging. Few studies suggested 
that EGFRvIII may occur in the absence of EGFR amplification in minor subsets of anaplastic 
astrocytomas and glioblastomas (11, 12). However, most studies indicate a close link 
between EGFR amplification and EGFRvIII expression (1, 9, 13), which both are nowadays 
considered as typical alterations in IDH-wildtype glioblastomas (6, 14, 15).  
 The prognostic role of EGFR amplification and EGFRvIII mutation in glioblastoma patients 
remains controversial. Individual studies suggested that these alterations are associated with 
shorter overall survival (OS) among anaplastic astrocytoma patients (12) and glioblastomas 
patients (11), while other authors found a prognostically favorable role of EGFRvIII positivity 
in glioblastoma patients (16). Yet other studies, including previous publications of the 
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German Glioma Network (13, 17), as well as a recent meta-analysis of eight publications 
(18), did not confirm a distinct prognostic role of EGFR amplification and EGFRvIII positivity, 
although a trend towards decreased long-term survival with EGFRvIII-positive glioblastoma 
has been reported (13, 19, 20). 
 Because of the ongoing development and clinical evaluation of various targeted treatment 
strategies directed against wildtype EGFR and/or against EGFRvIII (10), including e.g. 
peptide-based vaccines such as rindopepimut (21) and monoclonal antibody-based 
immunotoxins such as ABT-414 (22), a better understanding of the biological role and the 
prognostic significance of EGFR amplification and EGFRvIII status in glioblastoma is urgently 
needed. In particular, the prognostic role of EGFRvIII within the population of patients with 
EGFR-amplified glioblastoma has not been conclusively determined. Moreover, although 
most novel targeted agents are initially being tested in patients with progressive glioblastoma 
after failure of standard therapy consisting of local fractionated radiotherapy with concomitant 
and maintenance chemotherapy with temozolomide (TMZ/radiotherapy→TMZ), data 
regarding the expression and role of EGFRvIII in the recurrent setting are sparse and in part 
conflicting (23, 24). Accordingly, we explored the prognostic role of EGFRvIII expression 
among newly diagnosed patients with EGFR-amplified glioblastomas and determined the 
stability of EGFR amplification and the EGFRvIII status at recurrence following standard of 
care treatment. In a subset of patients, we performed targeted sequencing of the EGFR gene 
to evaluate additional EGFR sequence alterations for associations with EGFR gene 
amplification and prognosis, as well as for changes upon tumor recurrence. 
 
 
Patients and Methods 
 
Patients 
The present study was based on 106 patients with newly diagnosed EGFR-amplified, IDH-
wildtype glioblastomas. A total of 52 patients underwent second surgery for recurrent tumors. 
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From 40 of these patients, matched tissue specimens were available from primary and 
recurrent tumors (Supplementary Table 1). In addition, 33 primary and recurrent tumor pairs 
from patients with newly diagnosed, IDH-wildtype and EGFR-non-amplified tumors were 
studied (Supplementary Table 2). The patients were identified in the central database of the 
German Glioma Network (GGN) or the database of the Central Nervous System (CNS) tumor 
tissue bank at the Department of Neuropathology, Heinrich Heine University, Düsseldorf, 
Germany. They included 74 patients from the previous GGN study on the assessment of 
EGFRvIII expression in glioblastoma tissues obtained at first operation (13). The EGFRvIII 
status of the 106 primary tumors with EGFR amplification was determined by 
immunohistochemistry in 97 (91.5%) patients, by RT-PCR analysis in 88 (83.0%) patients 
and by both methods in 79 (74.5%) patients. For determination of changes in EGFR 
amplification and protein expression as well as EGFRvIII positivity between primary and 
recurrent glioblastomas, we additionally investigated recurrent glioblastoma tissue samples 
from 73 of the 85 patients who had second surgery (median interval between primary and 
recurrent resections in the 85 patients: 9.1 months, range: 3.3 – 42.7 months). In 12 patients, 
tissue from second surgery was either not available or not sufficient for further analyses.  The 
other 73 patients included 25 patients with EGFR-amplified and EGFRvIII-positive primary 
tumors, 15 patients with EGFR-amplified but EGFRvIII-negative primary tumors, and 33 
patients with EGFR-non-amplified tumors. Histology of the tumors was centrally reviewed 
and confirmed to correspond to glioblastoma World Health Organization (WHO) grade IV, 
originally based on the WHO classification of central nervous system tumors 2007 (25). All 
cases were later on shown to correspond to glioblastoma, IDH-wildtype, WHO grade IV 
according to the WHO classification of central nervous system tumors 2016 (26). Patients 
gave their written informed consent for participating in the German Glioma Network and the 
use of their tissue samples and clinical data for research purposes. The present study was 
approved by the institutional review board of the Medical Faculty, Heinrich Heine University, 
Düsseldorf, Germany (study number 4700). 
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Extraction of nucleic acids 
DNA and RNA were extracted from frozen tumor tissue samples either by ultracentrifugation 
(27, 28) or by using the JETQUICK Tissue DNA Spin Kit (Genomed, Loehne, Germany) and 
the RNeasy Mini Kit (Qiagen, Hilden, Germany). DNA and RNA preparation from formalin-
fixed and paraffin-embedded (FFPE) samples was performed with the QIAmp DNA FFPE 
Tissue Kit (Qiagen) and the RNeasy FFPE Kit (Qiagen).  
 
PCR-based detection of EGFR amplification and EGFRvIII rearrangement 
Detection of EGFR gene amplification by real-time PCR was performed as reported (29-31). 
The following primers were used for EGFR: EGFR-F (5'-cactgcctcatctctcaccatc-3') and 
EGFR-R (5'-gactcaccgtagctccagac-3'). Primers for the WI-3306 locus on 2q that served as 
reference locus were: WI-3306-F (5'-catgactgcgagcccaagatg-3') and WI-3306-R (5'-
caggtggtgtcatcagaatcag-3'). For each tumor, the target:reference gene ratio was normalized 
to the target:reference gene ratio of human normal brain DNA using the comparative ΔΔCT 
method. As positive control for EGFR gene amplification, we used tumor DNA extracted from 
a glioblastoma with known EGFR amplification. Only tumors showing a normalized 
target:reference gene ratio ≥ 3 were considered as showing EGFR gene amplification.  
 Detection of EGFRvIII positivity by qualitative RT-PCR has been reported elsewhere (13). 
The following primers located in EGFR exons 1 and 8 were used to generate products of 92 
bp for the EGFRvIII and 893 bp for EGFR wildtype (wt) mRNA sequences: EGFR-Ex1-F: 
GAGTCGGGCTCTGGAGGAAA; EGFR-Ex8-R: CCATCTCATAGCTGTCGGGCC. The 
EGFRwt product of 893 bb, however, was only detected in case when high-molecular weight 
RNA extracted from frozen tissue samples was used for cDNA generation. In case of RNA 
extracted from FFPE tissue samples, this fragment was usually not detectable due to RNA 
degradation. Therefore, we used additional primers located in exon 1 (as described above) 
and exon 2 (EGFR-Ex2-R: CAGTTATTGAACATCCTCTGGAG) generating a product of 111 
bp representing EGFR wildtype sequences (Figure 1). PCR was performed with HotStarTaq-
Polymerase (Qiagen) for 15 min at 95oC, followed by 40 cycles for 30 sec at 95oC, 30 sec at 
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60oC (EGFR-Ex1-F, EGFR-Ex8-R) or 58oC (EGFR-Ex1-F, EGFR- Ex2-R) and 1 min at 72oC 
(13) (Figure 1). 
 
Immunohistochemistry for EGFR and EGFRvIII protein 
Immunohistochemistry was performed as reported (13). For antigen retrieval, rehydrated 
sections were treated in 10 mM citrate buffer at pH 6.0 (for staining with E30 or 6549 
antibodies) or at pH 9.0 (for staining with DAK-H1-WT) for 20 min in a steamer. Sections 
were immunostained either with the mouse monoclonal antibody DAK- H1-WT (Dako, 
Copenhagen, Denmark) that detects only the wildtype EGFR protein (antibody dilution: 
1:200), a rabbit polyclonal antiserum (lot #6549, Celldex, Needham, MA) that exclusively 
detects the EGFRvIII protein (antibody dilution: 1:5000), or the monoclonal mouse antibody 
E30 (Dako) that detects both wildtype EGFR and EGFRvIII proteins (antibody dilution: 
1:200). Immunoreactivity for wildtype EGFR (DAK-H1-WT, E30) was semiquantitatively 
scored as follows: -, negative; +, weakly positive; ++, moderately positive; +++, strongly 
positive (32). EGFRvIII immunoreactivity was classified as positive when immunoreactive 
tumor cells were detectable (irrespective of the fraction of positive tumor cells) or as negative 
when immunoreactive tumor cells were absent (Figure 2). Evaluation of the 
immunohistochemical stainings was jointly performed by two experienced neuropathologists 
(J.F. and G.R.).  
 
Analysis for IDH mutation 
All tumors were screened for IDH1-R132H mutation using immunohistochemistry with the 
monoclonal antibody clone H09 (Dianova, Hamburg, Germany) (33). Tumors from patients 
younger than 55 years of age were additionally investigated for other IDH1 or IDH2 
mutations using Sanger sequencing or pyrosequencing as reported (29, 34) and 
recommended in the WHO classification 2016 (26). 
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O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation analysis 
The MGMT promoter methylation status was determined for all tumor samples using 
methylation-speciﬁc PCR (MSP) analysis as reported (35). Tumor DNA was treated with 
sodium bisulﬁte using the EZ DNA Methylation-Gold KitTM (HISS Diagnostics, Freiburg, 
Germany). DNA from the A172 glioma cell line (obtained from American Type Culture 
Collection, ATCC) was used as positive (methylated) control while peripheral blood leukocyte 
DNA served as negative (unmethylated) control. In addition, a no template DNA control was 
run with each experiment. 
 
Targeted sequencing of the EGFR coding sequence 
In a subset of 27 primary and recurrent paired glioblastoma samples, pairs (including 13 
pairs with and 14 pairs without EGFR amplification), we performed targeted next generation 
sequencing (NGS) of the EGFR coding sequence employing an amplicon-based approach 
for a pre-defined glioma gene panel and the Ion ProtonTM sequencing platform as reported 
(31). In total, 59 amplicons covering the entire EGFR coding region from exon 1 to exon 28 
were amplified from tumor DNA and sequenced. Evaluation of the NGS data for sequence 
variations and copy number alterations was performed as described in detail elsewhere (31).  
 
Evaluations involving The Cancer Genome Atlas (TCGA) data sets 
We retrieved data from 150 IDH-wildtype glioblastoma patients with available information on 
EGFR amplification and EGFR single nucleotide variants in the TCGA glioblastoma dataset 
(https://portal.gdc.cancer.gov/projects/TCGA-GBM). For a subset of these patients (n = 66) 
the EGFRvIII status was additionally available. Information concerning temozolomide 
therapy, overall survival, age at diagnosis, gender, MGMT promotor methylation status, and 
IDH mutation status, temozolomide therapy and OS were retrieved from the respective 
TCGA publications (14, 15). EGFR copy number data (GISTIC-scores) and EGFR mutation 
calls (SNVs) from the TCGA-GBM dataset were downloaded via the cBio Cancer Genomics 
Portal (www.cbioportal.org) using the open-source R package “cgsdr” (version 1.2.5) and the 
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statistical computing language R (version 3.3.2). Each case with at least one SNV in EGFR 
was classified as "SNV in EGFR". EGFR amplification was assumed if the GISTIC score was 
2. Cases with EGFRvIII allele frequencies (AF) > 0.01 as reported by Brennan et al. (14) 
were regarded as EGFRvIII-positive.  
 
Statistical analyses  
In the GGN cohort, progression-free survival (PFS) was calculated from the day of first 
surgery until tumor progression, death, or end of follow-up. Overall survival (OS) was 
calculated from the day of first surgery until death or end of follow-up. Kaplan-Meier survival 
curves and Logrank test as well as Cox regression analyses were used for univariate and 
multivariate analyses of survival data. Statistical analyses were performed with IBM SPSS 
Statistics version 24.0 or the R-package “survival” (version 2.40-1). To test for associations 
between EGFR-SNV status and EGFR amplification or EGFRvIII positivity, we used the 
Fisher's exact test from the basic R-package "stats" (version 3.3.2).  
 
 
Results 
 
Prognostic significance of EGFRvIII in EGFR-amplified glioblastoma 
The present study is based on 106 patients with EGFR-amplified, IDH-wildtype glioblastomas 
documented in the GGN central data base. Clinical characteristics, treatment and outcome of 
this patient cohort are summarized in Table 1 according to EGFRvIII status. EGFRvIII 
positivity was detetected in 60 of the 106 tumors (56.6%). EGFRvIII expression was 
detetected by immunohistochemistry in 49 of 97 tumors investigated (50.5%), while RT-PCR 
for EGFRvIII was positive in 50 of 88 tumors investigated (56.8%) (Supplementary Table 1). 
Among the 79 tumors evaluated for EGFRvIII by immunohistochemistry and RT-PCR, a total 
of 39 tumors were EGFRvIII-positive by both methods (49.4%) (Figures 1 and 2). All tumors 
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with immunohistochemical positivity for EGFRvIII were also EGFRvIII-positive by RT-PCR, 
whereas 9 tumors lacked immunohistochemical EGFRvIII positivity but showed positive 
results by RT-PCR, thus indicating a higher sensitivity of RT-PCR analysis or suppression of 
translation or both (Figures 1 and 2, Supplementary Table 1). EGFR-amplified glioblastomas 
generally showed strong and widespread immunopositivity with antibodies detecting wildtype 
EGFR proteins or both wildtype EGFR and EGFRvIII (Figure 2). In contrast, EGFRvIII 
immunopositivity was frequently restricted to subpopulations of tumor cells, with sometimes 
striking regional distribution (Supplementary Figure 1). 
Patients with EGFRvIII-positive tumors were slightly older (p=0.081) and less often had a 
high KPS (p=0.253) than patients with EGFR-amplified but EGFRvIII-negative glioblastomas 
(Table 1). However, PFS and OS did not differ in patients with EGFR-amplified glioblastomas 
stratified according to EGFRvIII status (Figure 3A-B). Hazard ratios (HR) with regard to PFS 
and OS were determined (HR=0.91, 95% CI 0.61-1.36, p=0.644; HR=1.05, 95% CI 0.70-
1.58, 0.798). HR were observed in the same order after adjustment for MGMT promoter 
methylation and first-line therapy (data not shown). EGFRvIII status was not associated with 
MGMT promoter methylation status (p=0.265). MGMT promoter methylation, but not 
EGFRvIII expression, was associated with longer OS in the 77 patients treated with 
radiotherapy and temozolomide chemotherapy (Supplementary Figure 2A-B). Further 
stratification of these patients according to EGFRvIII status and MGMT promoter methylation 
revealed that MGMT promoter methylation was associated with longer OS in patients with 
EGFRvIII-negative tumors but was not prognostic in patients with EGFRvIII-positive 
glioblastomas (Supplementary Figures 2C-D). 
 
Changes in EGFRvIII expression between paired primary and recurrent glioblastomas 
We investigated 40 glioblastoma patients with EGFR-amplified primary tumors who were 
treated by second surgery at progression and from whom representative tissue sections with 
viable tumor tissue were available from both primary and recurrent tumors. Of these, 25 
patients had EGFRvIII-positive primary tumors as detected by RT-PCR, 
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immunohistochemistry or both methods (Supplementary Table 1). Important patient 
characteristics are summarized in Table 1. Compared with patients who did not receive 
second surgery, patients with second surgery had more often received a gross total resection 
(28/44 patients versus 19/47 patients, p=0.027) and radiotherapy with concomitant and 
maintenance temozolomide chemotherapy (TMZ/radiotherapy→TMZ) as first-line treatment 
(43/52 patients versus 34/54 patients, p=0.023), but clinical characteristics were otherwise 
similar. One of the initially 15 EGFRvIII-negative tumors (by both immunohistochemistry and 
RT-PCR) became EGFRvIII-positive at recurrence by RT-PCR but not by 
Immunohistochemistry (Figure 1, patient 79). Among the recurrent tumors of the 25 initially 
EGFRvIII-positive patients undergoing second surgery, 21 patients (84%) retained EGFRvIII 
expression as detected by immunochemistry (15 patients, 71%), RT-PCR (18 patients, 86%) 
or both methods (12 patients, 57%) (Figures 1 and 2, Supplementary Table 1). In four 
patients, recurrent glioblastomas lost EGFRvIII positivity as determined by both methods for 
three patients and by immunohistochemistry for one patient  (Figures 1, 2 and 4, 
Supplementary Table 1). There were overall no major differences in clinical characteristics as 
well as PFS, OS, and post-recurrence survival between patients who did or did not receive a 
second operation when each group was stratified according to EGFRvIII status 
(Supplementary Figure 3). 
 To evaluate whether EGFRvIII-negative and EGFR-non-amplified glioblastomas may 
newly acquire EGFRvIII positivity and/or EGFR amplification, we additionally investigated 
paired primary and recurrent glioblastoma tissues samples from 33 patients with EGFR-non-
amplified primary glioblastomas. Recurrent tumors in none of these patients demonstrated 
newly acquired EGFR amplification or EGFRvIII positivity (Supplementary Table 2). 
 
Association of EGFR SNVs with EGFR amplification, tumor recurrence and OSpatient 
survival 
To assess a role of other EGFR sequence alterations other than EGFRvIII in glioblastoma 
recurrent glioblastomace, we performed next generation sequencing (NGS) of the EGFR 
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coding sequence in 27 paired samples of primary and recurrent glioblastomas, including 13 
paired samples with EGFR gene amplification. The detected EGFR SNVs generally 
corresponded to missense mutations, including several mutations previously reported in 
other studies as summarized in Supplementary Table 3. Since we performed NGS analyses 
for individual exons at the DNA level, we could not detect larger rearrangements and/or 
deletions previously reported (14), except for EGFRvIII. However, sensitivity of EGFRvIII 
detection by gene panel NGS was lower than withwhen compared to RT-PCR or 
immunohistochemistry (8/10 investigated tumors with EGFRvIII positivity), in line with 
published data (31). EGFR SNVs were found in eight of 13 EGFR-amplified primary tumors 
(including seven of 11 EGFRvIII-positive tumors and one of two EGFRvIII-negative tumors), 
but only in one of 14 EGFR-non-amplified primary tumors (p<0.01, Fisher's exact test). 
Presence of an EGFR missense mutation was not associated with distinct overall survivalOS 
in our cohort of 27 patients (Supplementary Figure 4).   
 In 11 of 14 GGN patients withone or more EGFR SNVs detected by NGS, the individual 
SNVs identified in the primary tumor were retained in the respective recurrence. In three 
patients, however, EGFR SNVs were lost from primary to recurrent tumor, while seven 
patients showed EGFR SNVs in their recurrent tumors that were not detectable in the 
matched primary tumors (Supplementary Table 3).  
 
Validation studies based on TCGA glioblastoma patients   
In line with the findings in the GGN cohort, interrogation of the TCGA database showed no 
OS difference in a cohort of 150 IDH-wildtype glioblastoma patients treated with 
temozolomide when patients were stratified according to EGFR amplification status or 
according to the presence of at least one EGFR SNV (Supplementary Figure 5A-B, 
Supplementary Table 5). Presence of EGFR SNVs was significantly associated with EGFR 
gene amplification in the TCGA cohort (25/79 EGFR-amplified glioblastomas versus 6/71 
EGFR-non-amplified tumors, p < 0.001). Within the group of 79 patients with EGFR-amplified 
glioblastomas, IDH-wildtype, additional presence of EGFR SNVs was not associated with 
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overall survivalOS (Supplementary Figure 5C). In the 66 cases with available information on 
EGFRvIII status, there was no association between the presence of an EGFR SNV and 
EGFRvIII positivity (3 SNV in EGFR-positive / 12 EGFRvIII-positive tumors versus 14  SNV in 
EGFR-positive / 54 EGFRvIII-negative tumors, p=0.95). Finally, EGFRvIII positivity was not 
associated with distinct OS in the subgroup of 32 TCGA patients with EGFR-amplified 
tumors and available information on EGFRvIII status (Supplementary Figure 5D).    
 
 
Discussion 
 
Interest in the biological role and the clinical significance of EGFR amplification and other 
EGFR alterations, in particular the constitutively active EGFRvIII deletion variant, in 
glioblastoma has increased over recent years. Accumulating preclinical evidence has 
attributed an important function of EGFRvIII-expressing glioblastoma cells in driving tumor 
heterogeneity and progression by promoting glioma cell proliferation, invasion, angiogenesis, 
stemness and therapy resistance in different model systems (36-43). In addition, several 
therapeutic approaches targeting overexpressed wildtype EGFR protein or specifically 
EGFRvIII have already entered, or are about to enter clinical evaluation, including peptide-
based vaccines (44-46), chimeric antigen receptor (CAR) T cells (47, 48), as well as anti-
EGFR antibody-based approaches (22, 49, 50). 
Previous studies reported on conflicting results concerning the prognostic role of 
EGFRvIII, with a meta-analysis of eight published studies indicating no obvious association 
of EGFR amplification or EGFRvIII positivity with survival of glioblastoma patients (18). Our 
present study confirms these data and additionally shows that the presence of EGFRvIII is 
not prognostic among patients with EGFR-amplified glioblastoma treated according to 
current standard of care (Table 1, Figure 1). 
In our patient cohort, MGMT promoter methylation was prognostic in patients treated with 
radiochemotherapy and was particularly associated with longer OS in the subgroup of 
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patients with EGFRvIII-negative tumors. In contrast, MGMT promoter methylation was not 
prognostic in the subgroup of patients with EGFRvIII-positive glioblastomas. However, we 
could not confirm the suggestion of a prognostic interaction between EGFRvIII expression 
and MGMT promoter methylation in a published data set of 13 patients with EGFRvIII 
positive tumors and available MGMT promoter methylation status (16), and in the large ACT 
IV phase 3 dataset (51).  
In line with previous studies, our immunohistochemical findings confirm that EGFR 
wildtype protein expression is strong and widespread in EGFR-amplified glioblastomas (11, 
17, 52). We did not assess regional heterogeniety of EGFR gene amplification. However, 
previous studies reported that EGFR amplification may be restricted to subpopulations of 
tumor cells in rare cases of glioblastomas with amplification of EGFR and PDGFRA (53, 54). 
With respect to EGFRvIII expression, our data demonstrate that EGFRvIII immunopositivity 
shows marked regional heterogeneity and is often restricted to subpopulations of tumor cells 
in glioblastomas, thus confirming previous findings in the GGN patient cohort (17) and in 
several independent studies (39, 42, 43, 52, 55).  
 We also addressed the clinically relevant question whether EGFR amplification and 
EGFRvIII expression may change from primary to recurrent glioblastomas following standard 
therapy. Montano et al. (56) reported on a trend towards lower expression of EGFRvIII in 
recurrent as opposed to corresponding primary glioblastomas based on the analysis of 13 
patients. Van den Bent et al. (23) investigated matched pairs of primary and recurrent 
glioblastomas from 55 patients, including 23 patients with tumors demonstrating high-copy 
EGFR amplification, and found that the EGFR amplification status remained stable in 46 of 
55 patients (84%). EGFRvIII mRNA expression as determined by RT-PCR was found to be 
lost from primary to recurrent tumors in 7 of 15 initially EGFRvIII-positive tumors. In contrast, 
other authors detected no loss of EGFRvIII positivity upon tumor recurrence following 
standard radiochemotherapy in 15 of 15 patients with EGFRvIII positive glioblastomas, while 
16 of 16 patients treated with anti-EGFRvIII vaccination demonstrated no more EGFRvIII 
expression upon tumor recurrence (24). In our study, we evaluated EGFR amplification and 
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expression at the DNA and protein levels, as well as EGFRvIII expression at the mRNA and 
protein levels. Thereby, we clearly demonstrated that EGFR amplification and the associated 
overexpression of EGFR protein in IDH-wildtype glioblastomas generally remain stable upon 
recurrence following standard therapy. In addition, investigation of 33 patients with EGFR 
non-amplified primary glioblastomas, IDH-wildtype, did not reveal a single patient whose 
tumor newly acquired EGFR amplification upon recurrence. EGFRvIII positivity persisted 
from primary to recurrent glioblastomas in 21 of 25 patients (84 %) with initially EGFRvIII-
positive tumors. However, glioblastomas in four patients had lost their initial EGFRvIII 
positivity upon recurrence while a single patient with an EGFR-amplified glioblastoma 
showed EGFRvIII positivity only in the recurrent tumor (Figure 4). The reason for the lower 
rate of tumors that lost EGFRvIII positivity upon recurrence in our cohort, as compared to the 
study of van den Bent et al. (23), are unclear. We carefully checked by histological review 
that all recurrent tumor specimens included in our series indeed contained vital cellular tumor 
tissue and not just reactive and reactive changes due to cytotoxic therapy, in particular 
radiotherapy. Thereby, we excluded false-negative findings due to insufficient tumor cell 
content and radiation necrosis. Thus, available data (23, present study) suggest that 
EGFRvIII expression may be lost following standard radiochemotherapy in a subset of 
patients, challenging the significance of previous observations reporting on loss of EGFRvIII 
positivity specifically in recurrent glioblastomas after peptide-based vaccinitation against 
EGFRvIII  but not after radiochemotherapy (24). Moreover, the finding that EGFRvIII 
expression is more commonly reduced or lost than increased or newly gained upon 
glioblastoma recurrence suggests a limited role of EGFRvIII in driving radiochemotherapy 
resistance and disease progression in glioblastoma patients, as suggested by studies in 
preclinical glioma models (36, 57).  
 Several studies have reported on various other EGFR sequence alterations than EGFRvIII 
in glioblastomas, including SNVs as well as larger rearrangements/deletions affecting the 
extracellular or intracellular domains (8, 14, 58-61). We therefore additionally  investigated a 
subset of 27 pairs of primary and recurrent glioblastomas for other EGFR gene mutations 
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using targeted next generation sequencing of tumor DNA. Thereby, we identified various 
EGFR SNVs leading to missense mutations, especially in tumors with EGFR gene 
amplification, thus corroborating data from other groups reporting on a frequent coincidence 
of EGFR amplification with other EGFR mutations (14, 58-60). Neither the results in our GGN 
cohort nor data from the TCGA consortium revealed evidence for an independent prognostic 
role of EGFR SNVs in patients treated according to the current standard of care. This finding 
reflects that EGFR SNVs are closely linked to EGFR amplification, which lacks prognostic 
significance in IDH-wildtype glioblastoma patients (13, 17, 18). Moreover, TCGA data do not 
support a prognostic role of EGFR SNVs among patients with EGFR-amplified glioblastomas 
(Supplementary Figure 54C).  
 We also investigated whether EGFR SNVs may change from primary to recurrent 
glioblastomas in individual patients. Similar to the findings for EGFRvIII, we observed that 
most of the EGFR SNVs detected in primary glioblastomas remain stable at recurrence. 
However, in three patients point mutations detected in primary tumors were lost upon 
recurrence while novel EGFR mutations turned up in recurrent glioblastomas of seven 
patients. These findings would be in line with a branched tumor evolution model, suggesting 
that recurrent glioblastomas following therapy may develop from minor subclones of the 
respective primary tumor. In addition, it is possible that EGFR point mutations detected 
exclusively in recurrent tumors are induced by therapy, in particular in case of C-G to T-A 
transitions that are known to be related to DNA-alkylating treatment with temozolomide (62). 
These issues require further analyses by more comprehensive molecular investigations of 
longitudinal biopsies in a larger cohort of glioblastoma patients.  
 In summary, our study shows that EGFRvIII is not prognostic in EGFR-amplified 
glioblastoma patients. EGFR amplification in glioblastomas is often associated with additional 
genetic changes including EGFRvIII and various SNVs. Upon tumor recurrence, the EGFR 
amplification status of the primary tumor is generally retained and the majority of EGFRvIII-
positive glioblastomas maintain EGFRvIII positivity at recurrence. However, EGFRvIII 
expression may change in a subset of patients at recurrence. Thus, in patients with recurrent 
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glioblastoma who are evaluated for EGFRvIII-directed therapy approaches, either on 
compassionate use or within clinical trials, re-assessment of the EGFRvIII status should be 
performed using recurrent glioblastoma tissue specimens to assure that the therapeutic 
target is still expressed on the tumor cells.   
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Legends to the Figures 
 
Figure 1. Agarose gel electrophoresis images of results obtained by RT-PCR for EGFR 
wildtype (wt) and EGFRvIII mRNA expression in pairs of primary tumors (PT) and recurrent 
tumors (RT) of five selected patients (1, patient 97; 2, patient 81; 3, patient 99; 4, patient 79; 
5, patient 100) with EGFR-amplified glioblastomas as demonstrated by real- time PCR (not 
shown).  Note that EGFRwt transcripts are expressed in all tumors as indicated by a 111 bp 
PCR product obtained by RT-PCR with primers detecting EGFR sequences in exons 1 and 
exon 2 (upper panel). In the lower panel. RT-PCR was performed with primers specific for 
EGFR exons 1 and exon 8, which amplify a 893 bp from EGFRwt transcripts and a 92 bp 
fragment from EGFRvIII transcripts. However, the 893-bp is obtained only when high-
molecular weight RNA extracted from frozen tissue is used as template (in case of normal 
brain, NB), but absent when degraded RNA from FFPE material is used (in case of the tumor 
samples). Patient 97 expressed EGFRvIII transcripts in both primary and recurrent tumor. 
Patient 81 lacked EGFRvIII expression in primary and recurrent tumor. In patient 99, 
EGFRvIII expression in the primary tumor was lost in the recurrent tumor; in contrast, patient 
79 had a clear EGFRvIII signal in the recurrent tumor that was absent in the primary tumor, 
while patient 100 showed a very weak, barely detectable EGFRvIII band in the primary tumor 
and a strong EGFRvIII signal in the recurrent tumor. C, controls: +, positive control with 
known EGFRvIII expression, NTC, non-template control (negative control). 
 
Figure 2. Representative immunohistochemical results obtained in four glioblastoma patients 
(A-D). Shown are histological features in hematoxylin-eosin (HE) stained sections and 
immunostainings for pairs of primary tumor (PT) and recurrent tumor (RT) from each patient. 
Immunohistochemical stainings were done using antibodies detecting wildtype EGFR 
(EGFRwt), wildtype EGFR and EGFRvIII (EGFRwt/vIII, E30) or EGFRvIII. All four depicted 
tumor pairs showed EGFR gene amplification (as demonstrated by real- time -PCR) as well 
strong immunoreactivity for EGFRwt and EGFRwt/vIII (E30). All immunostained sections are 
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counterstained with hemalum. While EGFRwt expression remained similar between primary 
and recurrent tumors, EGFRvIII expression changed in two of the depicted pairs. (A) Strong 
immunoreactivity for EGFRwt and EGFRvIII in the primary and recurrent tumor (patient 97). 
(B) Expression of EGFRwt but not EGFRvIII in the primary and recurrent tumor (patient 81). 
(C) Expression of EGFRwt and EGFRvIII in large areas of the primary tumor but loss of 
positivity for EGFRvIII in the recurrent tumor (patient 99). (D) Only a subpopulation of 
EGFRvIII-positive tumor cells in the primary tumor but widespread EGFRvIII positivity in the 
recurrent tumor (patient 100). Bars correspond to 100 µm.  
 
Figure 3. Survival outcome in 106 patients with EGFR-amplified glioblastomas, IDH-
wildtype, stratified according to the EGFRvIII status. (A) Progression-free survival (PFS) and 
(B) overall survival (OS) show no difference according to EGFRvIII status.  
 
Figure 4. Schematic representation of changes in EGFRvIII status in pairs of primary tumors 
(PT) and recurrent tumors (RT) of 73 patients with glioblastomas. Note that in 68 of the 73 
tumor pairs, EGFRvIII status remained identical from primary to recurrent tumor. In 5 tumor 
pairs, a change was observed, including 4 instances with loss of EGFRvIII positivity upon 
recurrence and a single instance with newly gained EGFRvIII positivity upon recurrence. 
EGFR amp., EGFR-amplified primary tumors; EGFR not. amp., EGFR-non-amplified primary 
tumors; EGFR amp. + EGFRvIII, EGFR-amplified and EGFRvIII-positive primary tumors. 
 
  
 0 
Table 1. Overview of the 106 patients with newly diagnosed EGFR-amplified glioblastoma, IDH-wildtype. Patient characteristics are stratified 
according to by EGFRvIII status at first surgery and according to treatment by second surgery.  
 
 EGFRvIII-
negative, 
all 
n=46 
 EGFRvIII-
positive, 
all 
n=60 
EGFRvIII-
negative, 
no second 
surgery 
n=25 
    EGFRvIII-
positive, 
no second 
surgery 
n=29 
  EGFRvIII-
negative, 
second surgery 
n=21 
   EGFRvIII-
positive, 
second surgery 
n=31 
Age at diagnosis       
  Median (years) 59 63 60 63 58 60 
  Range (years) 37-72 29-86 37-72 29-82 39-72 39-86 
Gender       
  Male 28 (60.9%) 40 (66.7%) 13 (52.0%) 20 (69.0%) 15 (71.4%) 20 (64.5%) 
  Female 18 (39.1%) 20 (33.3%) 12 (48.0%) 9 (31.0%) 6 (28.6%) 11 (35.5%) 
KPS at diagnosis       
  90-100 21 (50.0%) 17 (33.3%) 12 (48.0%) 7 (25.0%) 9 (52.9%) 10 (43.5%) 
  70-80 18 (42.9%) 28 (54.9%) 11 (44.0%) 16 (57.1%) 7 (41.2%) 12 (52.2%) 
  <70 3 (7.1%) 6 (11.8%) 2 (8.0%) 5 (17.9%) 1 (5.9%) 1 (4.3%) 
  No data 4 9  1 4 8 
Tumor location       
  Frontal 12 (26.1%) 14 (23.7%) 5 (20.0%) 7 (24.1%) 7 (33.3%) 7 (23.3%) 
  Temporal 11 (23.9%) 12 (20.3%) 6 (24.0%) 6 (20.7%) 5 (23.8%) 6 (20.0%) 
  Parietal 6 (13.0%) 9 (15.3%) 3 (12.0%) 5 (17.2%) 3 (14.3%) 4 (13.3%) 
  Occipital - 4 (6.8%) - 1 (3.4%) - 3 (10.0%) 
  Not localized to one site 14 (30.4%) 14 (23.7%) 8 (32.0%) 6 (20.7%) 6 (28.6%) 8 (26.7%) 
  Multifocal - 1 (1.7%) - 1 (3.4%) - - 
  Others 3 (6.5%) 5 (8.5%) 3 (12.0%) 3 (10.3%) - 2 (6.7%) 
  No data  1     1 
Surgery       
  Gross total resection 26 (60.5%) 21 (43.8%) 12 (50.0%) 7 (30.4%) 14 (73.7%) 14 (56.0%) 
  Subtotal resection (50-99%) 12 (27.9%) 22 (45.8%) 9 (37.5%) 13 (56.5%) 3 (15.8%) 9 (36.0%) 
  Partial resection (<50%) 3 (7.0%) 5 (10.4%) 2 (8.3%) 3 (13.0%) 1 (5.3%) 2 (8.0%) 
  Biopsy 2 (4.7%) - 1 (4.2%) - 1 (5.3%) - 
  No data 3 12 1 6 2 6 
-1- 
 
Histological subtype       
  Glioblastoma, IDH-wildtype 46 (100%) 59 (98.3%) 25 (100.0%) 28 (96.6%) 21 (100%) 31 (100%) 
  Gliosarcoma, IDH-wildtype - 1 (1.7%) - 1 (3.4%) - - 
MGMT promoter methylation 
status  
      
  Methylated 18 (39.1%) 30 (50.0%) 9 (36.0%) 18 (62.1%) 9 (42.9%) 12 (38.7%) 
  Unmethylated 28 (60.9%) 30 (50.0%) 16 (64.0%) 11 (37.9%) 12 (57.1%) 19 (61.3%) 
First-line treatment       
  Radiotherapy alone 9 (19.6%) 13 (21.7%) 9 (36.0%) 7 (24.1%) - 6 (19.4%) 
  TMZ/radiotherapy→TMZ * 34 (73.9%) 43 (71.7%) 15 (60.0%) 19 (65.5%) 19 (90.5%) 24 (77.4%) 
  TMZ cycles (median)  6 (1-25)  5 (1-24) 5 (2-12) 5 (1-24) 6 (1-25) 5 (1-10) 
  Patients with information on 
  number of TMZ cycles 
28/35 30/43 13/15 13/19 15/20 17/24 
  Chemotherapy alone 1 (2.2%) - - - 1 (4.8%) - 
  no therapy 2 (4.3%) 4 (6.7%) 1 (4.0%) 3 (10.3%) 1 (4.8%) 1 (3.2%) 
PD (events)       
  Salvage chemotherapy 21 (91.3%) 19 (76.0%) 9 (100.0%) 5 (83.3%) 12 (85.7%) 14 (73.7%) 
  Salvage radiotherapy 1 (4.3%) 2 (8.0%) - 1 (16.7%) 1 (7.1%) 1 (5.3%) 
  Salvage radio-/chemotherapy 1 (4.3%) 1 (4.0%) - - 1 (7.1%) 1 (5.3%) 
  other - 3 (12.0%) - - - 3 (15.8%) 
Survival       
  Median PFS (months, 95% CI) 8.2 (6.5-9.9) 8.7 (6.9-10.5) 8.2 (6.4-10.0) 7.4 (5.9-8.9) 7.7 (3.0-12.4) 9.6 (8.1-11.1) 
  Median OS (months, 95% CI) 17.0 (10.0-23.9) 16.8 (13.6-
20.1) 
13.3 (11.5-
15.0) 
9.9 (4.0-15.7) 21.3 (17.6-25.0) 24.0 (15.6-32.5) 
  Follow-up range (months) 7.5-26.9 10.7-94.6 - 94.6 7.5-26.9 10.7-48.4 
  Alive at last follow-up 3 (6.5%) 6 (10.0%) - 1 (3.5%) 3 (14.3%) 5 (16.1%) 
 
Abbreviations: CI, confidence interval; KPS, Karnofsky Performance Score; PD, progressive disease; TMZ, temozolomide; 
TMZ/radiotherapy→TMZ, radiotherapy with concomitant and maintenance TMZ; * includes six patients who received radiotherapy and adjuvant 
TMZ. 
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Supplementary Table 1. Overview of the individual survival times, MGMT promoter methylation status and results of EGFRvIII testing by 
immunohistochemistry (IHC) or reverse transcription-PCR (RT-PCR) in primary tumors (PT) and recurrent tumors (RT) of 106 patients with newly 
diagnosed EGFR-amplified glioblastomas, IDH-wildtype. PFS, progression-free survival; OS, overall survival; n.d., not determined; * deceased 
patients; ** no progression documented;  § excluded for Kaplan-Meier analyses because EGFRvIII was determined at second recurrence. 
 
Patient 
number 
Age 
(years) 
PFS 
(months) 
OS  
(months) 
MGMT promoter 
status 
PT 
EGFRvIII 
IHC 
PT 
EGFRvIII 
RT-PCR 
RT 
EGFRvIII 
IHC 
RT 
EGFRvIII 
RT-PCR 
1 46 16.0 23.1* unmethylated negative negative - - 
2 63 44.9 72.8* methylated negative n.d. - - 
3 66 1.5** 6.2* unmethylated negative negative - - 
4 50 9.7 27.2* unmethylated negative n.d. - - 
5 63 8.6 8.6* unmethylated negative n.d. - - 
6 60 5.0 14.2* methylated negative n.d. - - 
7 55 2.6 2.6* unmethylated negative negative - - 
8 37 16.1 21.4* methylated negative negative - - 
9 52 8.2 8.2* methylated negative negative - - 
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10 52 2.9 4.5* unmethylated n.d. negative - - 
11 61 8.0 9.0* unmethylated negative negative - - 
12 56 7.1 40.2* methylated negative negative - - 
13 66 23.0 49.7* methylated n.d. negative n.d. n.d. 
14 47 15.5 15.5* unmethylated negative negative - - 
15 62 11.4 15.0* methylated negative negative - - 
16 50 30.3 58.3* methylated negative n.d. - - 
17 67 7.5 20.9* methylated negative n.d. - - 
18 45 20.0 33.4* methylated negative negative - - 
19 61 5.9 8.7* unmethylated negative negative - - 
20 62 0.5 0.5* unmethylated negative negative - - 
21 56 3.5 6.0* methylated negative negative n.d. n.d. 
22 61 12.9 12.9* unmethylated negative negative - - 
23 53 2.2 10.4* methylated negative negative n.d. n.d. 
24 55 6.6 6.6* unmethylated negative negative - - 
25 57 4.8 12.6* unmethylated negative negative - - 
26 64 4.5 9.6* unmethylated negative negative - - 
27 72 4.8 13.3* unmethylated negative negative - - 
28 65 0.7 16.6* unmethylated n.d. negative n.d. n.d. 
29 71 13.6 13.6* unmethylated negative negative - - 
30 39 19.6 23.1* unmethylated n.d. negative n.d. n.d. 
31 54 12.8 19.7* unmethylated n.d. negative n.d. n.d. 
32 58 8.7 18.7* methylated negative positive - - 
33 76 6.0 6.0* methylated positive n.d. - - 
34 59 11.5 11.5* unmethylated positive positive - - 
35 47 11.2 30.0* methylated positive n.d. n.d. n.d. 
36 57 6.9 12.9* unmethylated positive n.d. n.d. n.d. 
37 69 11.6 11.6* unmethylated positive positive - - 
38 68 6.3 6.3* unmethylated positive positive - - 
39 37 2.1 2.1* methylated positive positive - - 
40 69 3.2** 9.1* methylated positive n.d. - - 
41 62 6.6 16.1* methylated positive n.d. - - 
42 50 9.9 9.9* methylated positive n.d. - - 
43 70 0.3 0.3* methylated positive positive - - 
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44 29 13.7 21.9* methylated positive positive - - 
45 59 9.0 11.2* unmethylated positive positive - - 
46 56 9.5 21.5* methylated positive positive - - 
47 56 32.3 39.6* unmethylated positive positive - - 
48 66 7.5 7.5* methylated positive positive - - 
49 57 2.3 2.3* methylated positive positive - - 
50 74 54.0 60.0* unmethylated positive positive - - 
51 75 5.1 5.1* unmethylated negative positive - - 
52 54 2.4 2.4* methylated positive positive - - 
53 68 2.2 2.6* unmethylated positive positive - - 
54 63 22.4 27.2* methylated positive positive n.d. n.d. 
55 70 6.7 9.6* unmethylated positive positive n.d. n.d. 
56 57 2.7 2.7* unmethylated negative positive - - 
57 76 5.5 10.8* methylated negative positive - - 
58 48 7.8 16.3* unmethylated positive positive n.d. n.d. 
59 54 8.3 11.6* methylated positive positive - - 
60 68 94.6** 94.6 methylated n.d. positive - - 
61 82 2.3 4.2* methylated positive positive - - 
62 63 7.1 7.1* unmethylated positive positive - - 
63 65 6.2 6.2* unmethylated positive positive - - 
64 57 16.6 34.9* methylated positive n.d. - - 
65 63 7.4 27.5* methylated positive positive - - 
66 86 3.0 24.9* methylated n.d. positive n.d. n.d. 
67 67 10.2 17.0* methylated negative negative negative negative 
68 58 8.7 20.4* unmethylated negative negative n.d. negative 
69 72 14.3 21.3* unmethylated negative negative negative n.d. 
70 50 5.2 13.2* unmethylated n.d. negative n.d. negative 
71 59 5.2 § 23.7* methylated n.d. negative n.d. negative 
72 52 30.4 54.5* methylated negative negative n.d. negative 
73 48 40.2 61.9* methylated negative negative n.d. negative 
74 71 3.7 41.2* unmethylated negative negative negative negative 
75 71 13.1 23.1* unmethylated negative n.d. negative n.d. 
76 58 12.0 50.4* unmethylated negative n.d. negative n.d. 
77 47 5.8 7.5 unmethylated negative negative negative negative 
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78 60 7.7 19.4 methylated negative negative negative negative 
79 50 4.6 21.2* unmethylated negative negative negative positive 
80 62 6.6 26.9 methylated negative negative negative negative 
81 61 3.1 13.9* unmethylated negative negative negative negative 
82 49 3.3 14.9* unmethylated negative positive positive positive 
83 54 6.5 11.0* methylated positive positive positive positive 
84 58 15.1 24.0* methylated positive positive negative negative 
85 70 3.8 12.3* methylated negative positive negative positive 
86 64 19.6 24.9* unmethylated positive positive positive n.d. 
87 63 13.0 17.9* unmethylated negative positive negative positive 
88 69 7.6 20.1* methylated positive positive positive positive 
89 57 18.1 26.1* methylated positive positive n.d. positive 
90 58 8.8 16.8* unmethylated negative positive n.d. positive 
91 56 21.3 33.2* methylated negative positive n.d. positive 
92 40 18.1 25.8* unmethylated positive positive n.d. positive 
93 60 7.0 § 61.0* methylated positive positive positive positive 
94 58 9.6 16.8* unmethylated positive positive positive positive 
95 67 3.9 18.8* unmethylated positive positive negative n.d. 
96 39 18.9 38.2* unmethylated positive positive negative negative 
97 73 9.2 12.2 unmethylated positive positive positive positive 
98 49 10.0 17.0* unmethylated positive positive positive positive 
99 64 9.6 10.7 unmethylated positive positive negative negative 
100 75 27.7 32.3* methylated positive positive positive positive 
101 71 23.9 37.0 unmethylated positive n.d. positive positive 
102 66 32.7 49.2* unmethylated positive n.d. positive n.d. 
103 55 3.0 § 20.8* unmethylated positive n.d. positive n.d. 
104 43 6.4 34.1 unmethylated positive positive positive positive 
105 72 26.1 48.4 methylated positive positive positive positive 
106 65 6.1 15.5* unmethylated positive positive positive positive 
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Supplementary Table 2. Overview of individual survival times, MGMT promoter methylation status and results of EGFRvIII testing by 
immunohistochemistry (IHC) or reverse transcription-PCR (RT-PCR) in primary tumors (PT) and recurrent tumors (RT) of 33 patients with newly 
diagnosed IDH-wildtype, EGFR-non-amplified glioblastomas. N.d., not determined. 
 
Patient 
number 
Age PFS 
(months) 
OS (months) MGMT promoter 
status 
PT PT RT RT 
(years) EGFRvIII EGFRvIII EGFRvIII EGFRvIII 
  IHC RT-PCR IHC RT-PCR 
107 64 10.3 25.3* methylated negative n.d. negative n.d. 
108 55 2.4 17.9* methylated negative n.d. negative n.d. 
109 68 3.6 16.7* unmethylated n.d. negative n.d. negative 
110 75 10.9 13.8* unmethylated negative n.d. negative n.d. 
111 67 3.7  21.9* methylated negative n.d. negative n.d. 
112 66 3.3    22.9* unmethylated negative n.d. negative n.d. 
113 53 42.7 47.5* methylated negative n.d. negative n.d. 
114 36 5.5 12.2* unmethylated negative n.d. negative n.d. 
115 33 8.4 13.7* methylated negative n.d. negative negative 
116 42 3.2 32.5 methylated negative n.d. negative n.d. 
117 59 5.2 15.8 unmethylated negative n.d. negative n.d. 
118 38 7.4 15.5 unmethylated negative n.d. negative n.d. 
119 46 5.5 12.7 methylated negative n.d. negative n.d. 
120 48 3.1  11.9 unmethylated negative n.d. negative n.d. 
121 54 3.4  23.7* methylated negative n.d. negative n.d. 
122 57 3.8 24.3 unmethylated negative n.d. negative n.d. 
123 61 2.9 16.1* unmethylated negative n.d. negative n.d. 
124 72 5.9 5.9 unmethylated negative n.d. negative n.d. 
125 72 12.2 41.4 unmethylated negative n.d. negative n.d. 
126 80 3.2 5.2 methylated negative n.d. negative n.d. 
127 47 6.7 16.8 unmethylated negative n.d. negative n.d. 
128 55 4.2 16.4* unmethylated negative n.d. negative n.d. 
129 53 4.2 14.0* methylated negative n.d. negative n.d. 
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130 69 5.4 12.5 unmethylated negative n.d. negative n.d. 
131 61 11.6 17.4* unmethylated negative n.d. negative n.d. 
132 57 7.8      79.5* methylated negative n.d. negative n.d. 
133 60 30.6 83.1* methylated negative n.d. negative n.d. 
134 58  3.7  16.0* methylated negative n.d. negative n.d. 
135 67 3.0 15.0* unmethylated negative n.d. negative n.d. 
136 53 3.1 15.9* methylated negative n.d. negative n.d. 
137 57 8.1 26.6* unmethylated negative n.d. negative n.d. 
138 43 12.4 21.7* unmethylated negative n.d. negative n.d. 
139 63 3.1 14.1* methylated negative n.d. negative n.d. 
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Supplementary Table 3. Overview of the EGFR single nucleotide variants (SNVs) detected by next generation sequencing (NGS) in primary (PT) 
and recurrent (RT) glioblastomas of 27 patients. Mutant allele frequencies in percent are provided for each SNV. References are provided for 
those SNVs that were already reported by other authors. The table also indicates the presence of EGFR amplification as detected by real time-
PCR or NGS, and EGFRvIII as detected by NGS or by immunohistochemistry (IMHC) and/or RT-PCR. Note that NGS detected all instances of 
EGFR amplification, but was less thansensitive compared to IHC?MH and/or RT-PCR in detecting EGFRvIII. 
 
Patient 
number 
PT / 
RT 
EGFR 
amplification 
(real time-
PCR) 
EGFR 
amplification 
(NGS) 
EGFRvIII 
(RT-PCR or 
IMH) 
EGFRvIII 
(NGS) 
 
EGFR SNVs (mutant allele frequencies in %) References 
69 PT + + - - c.G1793T:p.G598V (47);  
c.A2941C:p.I981L (96) 
59, 60 
RT + + - - c.G1793T:p.G598V (06);  
c.A2941C:p.I981L (79) 
59, 60 
79 PT + + - - -  
RT + + + + c.C1088T:p.T363I (47)  
83 PT + + + + -  
RT + + + + -  
84 PT + + + - -  
RT + + - - c.C866T:p.A289V (93) 59, 60 
87 PT + + + - c.T185G:p.L62R (94);  
c.G1562A:p.R521K (04);  
c.G1280A:p.R427H (07) 
 
RT + + + - c.T185G:p.L62R (07);  
c.G1562A:p.R521K (07);  
c.G1280A:p.R427H (22) 
 
90 PT + + + + -  
RT + + + + -  
93 PT + + + + c.C866A:p.A289D (11) 14, 59 
RT + + + - c.C866A:p.A289D (06) 59 
94 PT + + + - c.C574G:p.P192A (18)  
RT + + + - c.C574G:p.P192A (06)  
96 PT + + + - c.G1784A:p.C595Y (12)  
RT + + - - c.G2303T:p.S768I (04)  
97 PT + + + + c.A787C:p.T263P (70) 59 
RT + + + + c.A787C:p.T263P (70) 59 
98 PT + + + + c.G865A:p.A289T (15) 59 
Kommentiert [WM1]: Is this not more common? 
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RT + + + + -  
99 PT + + + + -  
RT + + - - c.C866T:p.A289V (29) 14, 59, 60 
100 PT + + + - c.G1793T:p.G598V (80)  
RT + + + + -  
108 PT - - - - -  
RT - - - - c.G2045A:p.G682D (07): 
 c.G3485Ap.S1162N (06) 
 
115 PT - - - - -  
RT - - - - -  
116 PT - - - - -  
RT - - - - c.G1793T:p.G598V (16) 59, 60 
117 PT - - - - -  
RT - - - - -  
118 PT - - - - -  
RT - - - - -  
119 PT - - - - -  
RT - - - - -  
120 PT - - - - -  
RT - - - - -  
123 PT - - - - c.C1787T:p.P596L (13) 59 
RT - - - - c.C1787T:p.P596L (10) 59 
124 PT - - - - -  
RT - - - - -  
125 PT - - - - -  
RT - - - - -  
126 PT - - - - -  
RT - - - - -  
127 PT - - - - -  
RT - - - - -  
135 PT - - - - -  
RT - - - - -  
137 PT - - - - -  
RT - - - - -  
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Supplementary Table 4. Overview of the validation cohort of 150 TCGA patients with IDH-wildtype glioblastoma (GBM). AF, allele frequency; WT, 
wildtype; M, methylated; UM, unmethylated; NA, not analyzed; TMZ, temozolomide.  
 
Case-ID Histology IDH 
status 
MGMT 
promoter 
status 
EGFR 
copy 
number 
[GISTIC
-score] 
EGFR 
SNV 
EGFRvIII 
positive 
[AF > 
0.01] 
Age 
[years] 
Gender Therapy Survival 
[months] 
Vital status 
[1: deceased; 
0: censored] 
TCGA-02-0055 GBM WT UM 1 - NA 62 female TMZ/radiation→TMZ 2.5 1 
TCGA-06-0124 GBM WT M 2 - NA 67 male Unspecified radiation→TMZ  20.4 1 
TCGA-06-0125 GBM WT M 2 G598V NA 63 female TMZ/radiation→TMZ 47.6 1 
TCGA-06-0130 GBM WT UM 1 - NA 54 male TMZ/radiation→TMZ 12.9 1 
TCGA-06-0132 GBM WT NA 2 - NA 49 male Standard radiation→TMZ 25.3 1 
TCGA-06-0139 GBM WT UM 1 - NA 40 male Standard radiation→TMZ 11.9 1 
TCGA-06-0141 GBM WT UM 1 - NA 62 male TMZ/radiation→TMZ 10.3 1 
TCGA-06-0168 GBM WT NA 1 - NA 59 female TMZ/radiation→TMZ 19.6 1 
TCGA-06-0169 GBM WT UM 2 - NA 68 male TMZ/radiation→TMZ 3.3 1 
TCGA-06-0171 GBM WT NA 1 - NA 65 male Non-standard radiation→TMZ 13.1 1 
TCGA-06-0184 GBM WT NA 2 - NA 63 male Standard radiation→TMZ 40.3 0 
TCGA-06-0185 GBM WT NA 2 V651M NA 54 male TMZ/radiation→TMZ 37.0 0 
TCGA-06-0188 GBM WT NA 1 - NA 71 male Standard radiation→TMZ 28.5 0 
TCGA-06-0189 GBM WT NA 2 - NA 55 male Standard radiation→TMZ 15.4 1 
TCGA-06-0190 GBM WT NA 1 - NA 62 male Standard radiation→TMZ 10.4 1 
TCGA-06-0237 GBM WT NA 2 L62R NA 75 female TMZ/radiation→TMZ 13.6 1 
TCGA-06-0238 GBM WT NA 1 - NA 46 male TMZ/radiation→TMZ 13.3 1 
TCGA-08-0386 GBM WT NA 2 - NA 74 male TMZ/radiation→TMZ 18.0 1 
TCGA-12-0615 GBM WT NA 2 - NA 78 female Non-standard radiation→TMZ 15.3 1 
TCGA-12-0616 GBM WT NA 2 G598V NA 36 female TMZ/radiation→TMZ 14.7 1 
TCGA-12-0618 GBM WT NA 1 - NA 49 male TMZ/radiation→TMZ 13.0 1 
TCGA-12-0619 GBM WT NA 2 G598V NA 60 male TMZ/radiation→TMZ 34.9 1 
TCGA-06-0644 GBM WT NA 1 - NA 71 male Standard radiation→TMZ 12.3 0 
TCGA-06-0646 GBM WT NA 2 - NA 60 male TMZ/radiation→TMZ 5.7 1 
TCGA-06-0648 GBM WT NA 1 - NA 77 male Standard radiation→TMZ 9.8 1 
TCGA-06-0650 GBM WT UM 2 - NA 39 female TMZ/radiation→TMZ 23.6 1 
TCGA-06-0686 GBM WT NA 2 - NA 53 male Standard radiation→TMZ 9.4 0 
TCGA-12-0688 GBM WT NA 2 - NA 74 male Standard radiation→TMZ 26.6 1 
TCGA-12-0692 GBM WT NA 1 - NA 75 female TMZ Chemo 3.6 1 
TCGA-15-0742 GBM WT NA 2 C636Y NA 65 male Non-standard radiation→TMZ 13.8 1 
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TCGA-06-0744 GBM WT NA 2 - NA 66 male Standard radiation→TMZ 19.5 0 
TCGA-14-0786 GBM WT M 2 A289V NA 50 female Standard radiation→TMZ 23.0 1 
TCGA-14-0789 GBM WT M 2 - NA 54 male TMZ/radiation→TMZ 11.2 1 
TCGA-14-0790 GBM WT M 2 A289V NA 64 female TMZ/radiation→TMZ 13.8 1 
TCGA-06-0875 GBM WT UM 1 - NA 61 female Standard radiation→TMZ 9.2 0 
TCGA-06-0876 GBM WT M 2 G598V 
R108K 
NA 72 female Standard radiation→TMZ 8.9 0 
TCGA-06-0878 GBM WT UM 2 - NA 74 male TMZ/radiation→TMZ 7.2 0 
TCGA-06-0879 GBM WT M 1 - NA 52 male Standard radiation→TMZ 23.0 0 
TCGA-06-0881 GBM WT UM 2 A289V NA 50 male Standard radiation→TMZ 5.8 0 
TCGA-06-0882 GBM WT UM 1 - NA 30 male TMZ/radiation→TMZ 5.4 0 
TCGA-06-0939 GBM WT UM 1 - NA 79 female TMZ/radiation→TMZ 20.9 0 
TCGA-26-1439 GBM WT UM 2 G598V NA 63 male TMZ/radiation→TMZ 13.9 1 
TCGA-14-1450 GBM WT M 1 - NA 57 female TMZ/radiation→TMZ 58.7 0 
TCGA-28-1747 GBM WT M 2 G598V 
H304Y 
+ 44 male Non-standard radiation→TMZ 2.5 1 
TCGA-14-1823 GBM WT M 2 A289T ´ 58 female TMZ/radiation→TMZ 17.8 1 
TCGA-14-1829 GBM WT UM 2 T363I ´ 57 male TMZ/radiation→TMZ 7.2 0 
TCGA-27-1830 GBM WT UM 1 - ´ 57 male Standard radiation→TMZ 5.1 1 
TCGA-27-1831 GBM WT UM 2 R108K ´ 66 male TMZ/radiation→TMZ 16.6 1 
TCGA-27-1832 GBM WT UM 2 - ´ 59 female Non-standard radiation→TMZ 9.9 1 
TCGA-27-1833 GBM WT UM 2 - NA 67 female Standard radiation→TMZ 24.2 1 
TCGA-27-1834 GBM WT M 1 - ´ 56 male TMZ/radiation→TMZ 40.5 1 
TCGA-27-1835 GBM WT M 1 - ´ 53 female TMZ/radiation→TMZ 21.3 1 
TCGA-27-1836 GBM WT M 2 - NA 33 female TMZ/radiation→TMZ 30.0 1 
TCGA-27-1837 GBM WT M 2 - ´ 36 male Standard radiation→TMZ 14.0 1 
TCGA-27-1838 GBM WT UM 2 A289D NA 59 female Standard radiation→TMZ 11.5 1 
TCGA-32-1970 GBM WT UM 1 A289V ´ 59 male TMZ/radiation→TMZ 15.4 1 
TCGA-32-1986 GBM WT UM 1 - NA 68 male Standard radiation→TMZ 12.7 1 
TCGA-32-1991 GBM WT UM 2 - NA 60 male TMZ/radiation→TMZ 16.9 1 
TCGA-02-2470 GBM WT UM 1 - NA 57 male TMZ/radiation→TMZ 12.9 1 
TCGA-02-2485 GBM WT UM 1 A289D ´ 53 male TMZ/radiation→TMZ 15.4 0 
TCGA-02-2486 GBM WT UM 1 - ´ 64 male TMZ/radiation→TMZ 16.2 0 
TCGA-32-2491 GBM WT UM 1 - NA 63 male TMZ/radiation→TMZ 12.2 1 
TCGA-32-2494 GBM WT M 2 - NA 58 female TMZ/radiation→TMZ 20.8 1 
TCGA-32-2495 GBM WT UM 2 - NA 59 female TMZ/radiation→TMZ 15.0 1 
TCGA-28-2509 GBM WT M 1 - ´ 77 female Standard radiation→TMZ 4.8 0 
TCGA-28-2513 GBM WT UM 2 - ´ 69 female TMZ/radiation→TMZ 7.3 0 
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TCGA-28-2514 GBM WT UM 2 - ´ 45 male Standard radiation→TMZ 5.3 0 
TCGA-27-2518 GBM WT UM 2 - NA 52 male TMZ/radiation→TMZ 24.7 1 
TCGA-27-2519 GBM WT UM 1 - ´ 48 male TMZ/radiation→TMZ 10.4 0 
TCGA-27-2523 GBM WT M 2 - ´ 63 male Standard radiation→TMZ 16.1 1 
TCGA-27-2524 GBM WT UM 1 - ´ 56 male Standard radiation→TMZ 7.6 1 
TCGA-27-2528 GBM WT M 2 R222C ´ 62 male TMZ/radiation→TMZ 15.8 1 
TCGA-06-2559 GBM WT M 1 - ´ 83 male TMZ/radiation→TMZ 4.9 1 
TCGA-06-2561 GBM WT UM 1 R149W ´ 53 female TMZ/radiation→TMZ 9.3 0 
TCGA-06-2562 GBM WT UM 1 - ´ 81 male NonStandard radiation→TMZ 2.8 0 
TCGA-06-2563 GBM WT M 2 R252C ´ 72 female TMZ/radiation→TMZ 8.5 0 
TCGA-06-2564 GBM WT UM 2 - + 50 male Non-standard radiation→TMZ 5.9 0 
TCGA-06-2565 GBM WT M 2 R108K ´ 59 male TMZ/radiation→TMZ 6.8 0 
TCGA-06-2567 GBM WT M 1 - ´ 65 male Non-standard radiation→TMZ 4.4 1 
TCGA-41-2571 GBM WT UM 1 - ´ 89 male TMZ Chemo 0.9 1 
TCGA-41-2572 GBM WT UM 2 - ´ 67 male TMZ/radiation→TMZ 13.3 1 
TCGA-41-2573 GBM WT M 1 - NA 59 male TMZ/radiation→TMZ 8.9 0 
TCGA-41-2575 GBM WT UM 2 - NA 75 male TMZ/radiation→TMZ 9.5 1 
TCGA-32-2615 GBM WT UM 2 - ´ 62 male Non-standard radiation→TMZ 15.9 1 
TCGA-19-2619 GBM WT M 2 - ´ 55 female TMZ/radiation→TMZ 9.7 0 
TCGA-19-2620 GBM WT M 2 G598V + 70 male TMZ/radiation→TMZ 4.9 1 
TCGA-19-2623 GBM WT M 1 - NA 65 male TMZ/radiation→TMZ 7.5 0 
TCGA-32-2634 GBM WT M 0 - ´ 82 male TMZ/radiation→TMZ 8.9 0 
TCGA-32-2638 GBM WT M 2 - ´ 67 male TMZ/radiation→TMZ 7.4 0 
TCGA-41-3393 GBM WT UM 2 - NA 81 female TMZ/radiation→TMZ 4.4 1 
TCGA-12-3649 GBM WT UM 2 - NA 76 male TMZ Chemo 15.2 1 
TCGA-12-3650 GBM WT UM 2 A289V ´ 46 male TMZ/radiation→TMZ 10.9 1 
TCGA-12-3652 GBM WT UM 2 R252P + 60 male TMZ/radiation→TMZ 34.9 1 
TCGA-12-3653 GBM WT UM 2 - ´ 34 female TMZ/radiation→TMZ 14.5 1 
TCGA-41-3915 GBM WT M 1 - ´ 48 male TMZ/radiation→TMZ 6.0 0 
TCGA-32-4211 GBM WT UM 1 - NA 56 male TMZ/radiation→TMZ 12.6 1 
TCGA-32-4213 GBM WT M 2 - ´ 47 female TMZ/radiation→TMZ 11.7 0 
TCGA-32-4719 GBM WT UM 2 - NA 73 male TMZ/radiation→TMZ 10.8 1 
TCGA-76-4925 GBM WT M 1 - ´ 76 male NonStandard radiation→TMZ 4.8 1 
TCGA-76-4926 GBM WT UM 2 - + 68 male NonStandard radiation→TMZ 4.5 1 
TCGA-76-4928 GBM WT M 1 - ´ 85 female NonStandard radiation→TMZ 3.1 1 
TCGA-76-4931 GBM WT UM 2 G598V ´ 70 female NonStandard radiation→TMZ 9.2 1 
TCGA-76-4935 GBM WT M 1 - NA 52 female Standard radiation→TMZ 10.8 0 
TCGA-26-5132 GBM WT M 2 - + 74 male TMZ/radiation→TMZ 9.4 0 
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TCGA-26-5133 GBM WT UM 0 - ´ 59 male TMZ/radiation→TMZ 14.9 0 
TCGA-28-5204 GBM WT UM 2 - + 72 male TMZ/radiation→TMZ 14.9 1 
TCGA-28-5207 GBM WT UM 1 A289T ´ 71 male NonStandard radiation→TMZ 11.3 1 
TCGA-28-5208 GBM WT M 1 - ´ 52 male TMZ/radiation→TMZ 15.6 0 
TCGA-28-5209 GBM WT M 2 G598A ´ 66 female NonStandard radiation→TMZ 2.5 0 
TCGA-28-5211 GBM WT UM 2 - NA 42 male TMZ/radiation→TMZ 11.8 0 
TCGA-28-5213 GBM WT UM 1 G598V ´ 72 male Standard radiation→TMZ 9.8 0 
TCGA-28-5214 GBM WT UM 2 - NA 53 male NonStandard radiation→TMZ 14.2 0 
TCGA-28-5215 GBM WT M 1 - ´ 62 female NonStandard radiation→TMZ 11.0 1 
TCGA-28-5216 GBM WT UM 0 - ´ 52 male TMZ/radiation→TMZ 13.6 0 
TCGA-28-5218 GBM WT UM 1 - ´ 63 male Standard radiation→TMZ 5.2 1 
TCGA-28-5219 GBM WT M 1 - NA 47 female NonStandard radiation→TMZ 8.5 0 
TCGA-28-5220 GBM WT UM 1 - + 67 male Standard radiation→TMZ 10.5 0 
TCGA-32-5222 GBM WT M 1 - ´ 66 male TMZ/radiation→TMZ 5.4 0 
TCGA-12-5295 GBM WT M 2 - + 60 female TMZ/radiation→TMZ 14.9 1 
TCGA-12-5299 GBM WT UM 1 - ´ 56 female TMZ/radiation→TMZ 3.2 1 
TCGA-12-5301 GBM WT M 1 - NA 59 male TMZ/radiation→TMZ 2.0 1 
TCGA-06-5408 GBM WT UM 2 - + 54 female Standard radiation→TMZ 11.7 1 
TCGA-06-5411 GBM WT UM 1 - ´ 51 male Standard radiation→TMZ 8.3 1 
TCGA-06-5412 GBM WT M 1 - ´ 78 female Standard radiation→TMZ 4.5 1 
TCGA-06-5413 GBM WT UM 2 - ´ 67 male Standard radiation→TMZ 8.8 0 
TCGA-06-5414 GBM WT UM 2 - + 61 male TMZ/radiation→TMZ 9.0 0 
TCGA-06-5415 GBM WT UM 2 - + 60 male TMZ/radiation→TMZ 8.5 0 
TCGA-41-5651 GBM WT M 1 - ´ 59 female TMZ/radiation→TMZ 11.5 0 
TCGA-06-5858 GBM WT UM 1 - ´ 45 female TMZ/radiation→TMZ 6.1 0 
TCGA-06-5859 GBM WT UM 1 - ´ 63 male TMZ/radiation→TMZ 4.6 0 
TCGA-19-5950 GBM WT M 2 - NA 52 female TMZ/radiation→TMZ 11.3 0 
TCGA-19-5951 GBM WT UM 2 - NA 76 female TMZ/radiation→TMZ 8.0 1 
TCGA-19-5954 GBM WT M 2 - NA 72 female TMZ/radiation→TMZ 8.0 0 
TCGA-19-5958 GBM WT UM 1 - NA 56 male TMZ/radiation→TMZ 5.4 0 
TCGA-19-5959 GBM WT M 2 - NA 77 female TMZ/radiation→TMZ 5.3 0 
TCGA-19-5960 GBM WT UM 1 - ´ 56 male TMZ/radiation→TMZ 5.4 0 
TCGA-26-6173 GBM WT UM 2 - NA 57 male TMZ/radiation→TMZ 7.9 0 
TCGA-26-6174 GBM WT M 1 - NA 65 female TMZ/radiation→TMZ 2.3 0 
TCGA-76-6191 GBM WT UM 1 C620W NA 57 male TMZ/radiation→TMZ 16.7 1 
TCGA-76-6192 GBM WT UM 1 - NA 74 male Standard radiation→TMZ 3.3 1 
TCGA-76-6193 GBM WT UM 0 - NA 78 male Standard radiation→TMZ 2.7 1 
TCGA-76-6282 GBM WT UM 2 C571S NA 63 male TMZ/radiation→TMZ 17.1 1 
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TCGA-76-6285 GBM WT UM 1 - NA 64 female TMZ Chemo 8.3 1 
TCGA-06-6388 GBM WT UM 1 - NA 64 female TMZ/radiation→TMZ 5.2 1 
TCGA-06-6390 GBM WT UM 1 - NA 58 male TMZ/radiation→TMZ 5.4 1 
TCGA-28-6450 GBM WT UM 2 - NA 60 male TMZ/radiation→TMZ 5.4 1 
TCGA-74-6573 GBM WT UM 2 - NA 67 male TMZ/radiation→TMZ 3.4 1 
TCGA-06-6695 GBM WT M 1 - NA 64 male TMZ/radiation→TMZ 8.3 0 
TCGA-06-6698 GBM WT UM 1 - NA 53 female Non-standard radiation→TMZ 4.8 0 
TCGA-06-6700 GBM WT M 2 - NA 76 male TMZ/radiation→TMZ 4.8 0 
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Supplementary Figures 
 
 
Supplementary Figure 1. Demonstration of regional heterogeneity of EGFRvIII expression 
in an EGFR-amplified primary glioblastoma, IDH-wildtype (patient 96). Shown are 
consecutive sections immunstained with antibodies against EGFR wildtype (EGFRwt, left 
side) and EGFRvIII (EGFRwt, right side). Note that EGFRwt expression is homogeneously 
distributed across the entire tumor specimen. In contrast, EGFRvIII-positivity is restricted to a 
subpopulation of tumor cells in the left upper area of the tumor while the tumor parts on the 
right-hand side are mostly negative for EGFRvIII. Sections are counterstained with hemalum. 
Scale bars correspond to 50 µm in the high magnification images at the top and 500 µm in 
the low magnification images at the bottom.   
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Supplementary Figure 2. EGFRvIII expression and MGMT promoter methylation status and 
survival outcome in 77 patients with EGFR-amplified glioblastomas treated with radiotherapy 
and temozolomide chemotherapy. (A) Overall survival (OS) in the 77 patients stratified 
according to EGFRvIII status. (B) OS in the 77 patients stratified according to MGMT 
promoter methylation status. (C)  OS in the subgroup of patients with EGFRvIII-negative 
tumors stratified according to MGMT promoter methylation status. (D)  OS in the subgroup of 
patients with EGFRvIII-positive tumors stratified according to MGMT promoter methylation 
status.  
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Supplementary Figure 3. Survival of patients with EGFR-amplified glioblastomas, IDH-
wildtype, according to the EGFRvIII status in the subgroups of patients who received second 
surgery (52 patients) or did not receive second surgery (54 patients). (A) PFS and (B) OS in 
patients who did not receive second surgery. (C) PFS and (D) OS in patients who received 
second surgery. Post-first progression PFS and OS from first progression in patients who 
were not re-operated (E,F) or were re-operated (G,H). 
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Fehlt noch aus Leipzig 
 
 
 
 
 
 
Supplementary Figure 4. Survival of 27 German Glioma Network patients with 
glioblastoma, IDH-wildtype, according to presence (14 patients) or absence (13 patients) of 
at least one EGFR single nucleotide variant (SNV) as detected by NGSnext generation 
sequencing of the EGFR coding sequence.  
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Supplementary Figure 5. Survival of TCGA patients with glioblastoma, IDH-wildtype, 
according to EGFR amplification, presence of at least one EGFR single nucleotide variant 
(SNV), or EGFRvIII positivity. (A) OS in 150 TCGA patients with glioblastoma, IDH-wildtype, 
stratified according to presence (79 patients) or absence (71 patients) of EGFR gene 
amplification EGFR SNVs. (B) OS in 150 TCGA patients with glioblastoma, IDH-wildtype, 
stratified according to presence (31 patients) or absence (119 patients) of at least one EGFR 
SNV. (C) OS in 79 TCGA patients with EGFR-amplified glioblastoma, IDH-wildtype, stratified 
according to presence (25 patients) or absence (54 patients) of at least one EGFR SNV. (D) 
OS in 33 TCG patients with EGFR-amplified glioblastoma, IDH-wildtype, stratified according 
to presence (11 patients) or absence (21 patients) of EGFRvIII posiivity. Note that neither 
EGFR amplification nor presence of EGFR SNVs were associated with OS in the entire 
patient cohort (A-B). Within the subgroup of EGFR-amplified glioblastoma patients, neither 
presence of EGFR SNVs nor EGFRvIII were associated withto OS (C-D). 




